GlassScriptPhysician profile
William B Buselmeier
NPI 1548608375
$1,521.26
in general payments reported to CMS, 2019-2025
21 companies · $903 in 2025
The $903 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $104 · 2022: $20.12 · 2023: $91.19 · 2024: $404 · 2025: $903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,397.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $304.39 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $199.42 | 2025 | |
| Glaxosmithkline, LLC. | $169.96 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $125.88 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $104.16 | 2021-2023 | |
| Pfizer INC. | $94.14 | 2024-2025 | |
| Dexcom, INC. | $68.41 | 2024-2025 | Dexcom G6 Transmitter |
| Alnylam Pharmaceuticals INC. | $59.46 | 2024 | Givlaari |
| Lilly USA, LLC | $53.55 | 2024 | Mounjaro, Zepbound, Jardiance |
| Axsome Therapeutics, INC. | $49.48 | 2025 | Auvelity |
| Exact Sciences Corporation | $48.19 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.76 | 2024-2025 | Xifaxan |
| Dynavax Technologies Corporation | $34.87 | 2024-2025 | Heplisav-B |
| Lundbeck LLC | $31.71 | 2025 | Vyepti |
| Astellas Pharma US INC | $26.24 | 2025 | Veozah |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $23.90 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.95 | 2025 | Jardiance |
| Tonix Medicines, INC. | $16.83 | 2025 | Tonmya |
| Inogen, INC. | $16.30 | 2024 | |
| Amgen INC. | $16.06 | 2025 | Krystexxa |
| Esperion Therapeutics, INC. | $14.60 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Buselmeier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.